Zytiga Tablet
Product Images NDC 57894-150

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zytiga (NDC 57894-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zytiga 01)

Chemical structure diagram of abiraterone acetate, the active ingredient in Zytiga tablets. The structure shows its steroidal backbone with acetate and pyridine functional groups distinctly illustrated.*

FDA Label Image

Figure 1 (Zytiga 02)

A Kaplan-Meier survival curve comparing the percentage survival over time in months between Zytiga (Abiraterone acetate) and placebo groups. The graph shows time to death in months on the x-axis and percent survival on the y-axis, with Zytiga and placebo represented by separate lines.*

FDA Label Image

Figure 2 (Zytiga 03)

A Kaplan-Meier survival curve graph depicting the percentage of subjects without death over time in months from randomization for Zytiga and Placebo groups. The x-axis shows time in months, and the y-axis shows the percentage of subjects without death. Two lines represent survival rates for Zytiga and Placebo, with Zytiga showing higher survival over the study period.*

FDA Label Image

Figure 3 (Zytiga 04)

A Kaplan-Meier survival curve chart comparing the percentage of subjects without radiographic progression or death over time (months from randomization) between Zytiga and placebo groups. The chart shows two stepwise curves, with Zytiga's curve consistently above the placebo's, indicating a higher percentage of progression-free subjects over an 18-month period.*

FDA Label Image

Principal Display Panel (250 mg Bottle Label)

A Kaplan-Meier survival curve chart showing the percentage survival of subjects without death over months from randomization. It compares two groups: Zytiga and Placebo. The survival rate for Zytiga remains higher than Placebo throughout the study period, with data points for the number of subjects at risk at specified time intervals.*

FDA Label Image

Principal Display Panel (250 mg Tablet Bottle Label 184-12)

Zytiga (abiraterone acetate) 250 mg film-coated tablets label. The label includes dosage strength, a warning for women who may be pregnant, instructions to swallow whole without crushing or chewing, storage conditions, and Janssen Biotech as the manufacturer. The package contains 120 tablets and notes the product is made in Belgium.*

FDA Label Image

Principal Display Panel (500 mg Bottle Label)

Zytiga 500 mg film-coated tablets label showing active ingredient abiraterone acetate. The label includes dosage instructions, storage conditions (20°C to 25°C), and a warning to swallow the tablet whole without crushing or chewing. The package contains 60 tablets and is manufactured by Janssen Biotech, Inc., Horsham, PA, with product origin Belgium indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.